Pricing
  1. US-listed companies
  2. HALOZYME THERAPEUTICS, INC.
  3. Financials
  4. EBITDA

HALOZYME THERAPEUTICS, INC. (HALO)

Market cap
$7.9B
P/E ratio
SummaryFinancials
Period EndEBITDA (Million USD)YoY (%)
Dec 31, 2024562+61.12%
Dec 31, 2023349+27.24%
Dec 31, 2022274-1.75%
Dec 31, 2021279+89.02%
Dec 31, 2020148-332.33%
Dec 31, 2019-64-5.13%
Dec 31, 2018-67-180.46%
Dec 31, 201783-202.97%
Dec 31, 2016-81+213.48%
Dec 31, 2015-26-57.93%
Dec 31, 2014-61-22.64%
Dec 31, 2013-79+50.74%
Dec 31, 2012-53+180.35%
Dec 31, 2011-19

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat